Catastrophic antiphospholipid syndrome

被引:29
作者
Merrill, JT
Asherson, RA
机构
[1] Oklahoma Med Res Fdn, Clin Pharmacol Res Program, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Norman, OK 73019 USA
[3] Univ Cape Town, Hlth Sci Ctr, Dept Med, Rheumat Dis Unit, ZA-7925 Cape Town, South Africa
[4] Rosebank Clin, Johannesburg, South Africa
[5] Hosp Clin Barcelona, Syst Autoimmune Dis Unit, Barcelona, Spain
来源
NATURE CLINICAL PRACTICE RHEUMATOLOGY | 2006年 / 2卷 / 02期
关键词
antiphospholipid; catastrophic; microangiopathy; thrombosis;
D O I
10.1038/ncprheum0069
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiphospholipid syndrome (APS) is a thrombotic disorder associated with autoantibodies that target membrane phospholipids and phospholipid-bin ding proteins, which regulate coagulation. APS is usually characterized by major arterial or venous occlusions, pregnancy complications, or both. In 1992, Asherson described an unusual variant of APS termed the catastrophic antiphospholipid syndrome (also known as Asherson's syndrome), the hallmark of which is rapid multiorgan failure caused by widespread small-vessel thrombi. Empiric treatments have improved the prognosis of patients, but half still die from thrombotic diathesis, even though those who survive the acute stages frequently remain well. Given the persistently high mortality rate, efforts have been underway to facilitate early diagnosis, institute effective treatments in a timely manner and to better understand the cause (or causes) of this extreme condition in order to improve outcomes.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 45 条
[1]   Catastrophic antiphospholipid syndrome: Remission following leg amputation in 2 cases [J].
Amital, H ;
Levy, Y ;
Davidson, C ;
Lundberg, I ;
Harju, A ;
Kosach, Y ;
Asherson, RA ;
Shoenfeld, Y .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2001, 31 (02) :127-132
[2]   Catastrophic antiphospholipid syndrome -: Clinical and laboratory features of 50 patients [J].
Asherson, RA ;
Cervera, R ;
Piette, JC ;
Font, J ;
Lie, JT ;
Burcoglu, A ;
Lim, K ;
Muñoz-Rodríguez, FJ ;
Levy, RA ;
Boué, F ;
Rossert, J ;
Ingelmo, M .
MEDICINE, 1998, 77 (03) :195-207
[3]   Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome:: clinical and haematological characteristics of 23 patients [J].
Asherson, RA ;
Espinosa, G ;
Cervera, R ;
Gómez-Puerta, JA ;
Musuruana, J ;
Bucciarelli, S ;
Ramos-Casal, M ;
Martínez-González, AL ;
Ingelmo, M ;
Reverter, JC ;
Font, J ;
Triplett, DA .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :943-946
[4]   The catastrophic antiphospholipid (Asherson's) syndrome in 2004 - a review [J].
Asherson, RA .
AUTOIMMUNITY REVIEWS, 2005, 4 (01) :48-54
[5]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[6]   The catastrophic antiphospholipid syndrome 1996: Acute multi-organ failure associated with antiphospholipid antibodies: A review of 31 patients [J].
Asherson, RA ;
Piette, JC .
LUPUS, 1996, 5 (05) :414-417
[7]  
ASHERSON RA, 1992, J RHEUMATOL, V19, P508
[8]   Catastrophic antiphospholipid syndrome [J].
Asherson, RA ;
Cervera, R .
CURRENT OPINION IN HEMATOLOGY, 2000, 7 (05) :325-329
[9]   Catastrophic antiphospholipid syndrome [J].
Ronald A. Asherson ;
Ricard Cervera .
Current Rheumatology Reports, 2003, 5 (5) :395-400
[10]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709